Diagnostica Stago Inc.

Diagnostica Stago Inc., a foreign-owned manufacturer of hemostasis and thrombosis testing equipment, operates as a prime contractor delivering specialized coagulation analyzers, reagents, controls, and maintenance services to federal healthcare agencies through open competition without set-aside designations. Headquartered in Parsippany, New Jersey, the company has maintained federal contractor status since November 2001 and competes predominantly on full-and-open procurements under the GSA Schedule 66-III for Critical Analyzers, Laboratory Equipment and Supplies.

The company's federal footprint concentrates heavily on hemostasis and thrombosis diagnostic products. Representative prime work includes a $500,000 single-award BPA with Veterans Integrated Service Network 9 (May 2026–April 2027) for cost-per-reportable-result coagulation testing and equipment lease services across VISN 9 medical facilities in Tennessee and Kentucky; a $3.6 million single-award BPA with VISN 6 (October 2024–September 2029) for coagulation testing equipment, reagents, controls, and maintenance; and a $1.3 million Defense Health Agency BPA (March 2025–March 2030) for diagnostic supplies, reagents, and consumables. More recent task orders include delivery orders from the Defense Health Agency for STA R Max and STA Compact Max coagulation instruments and reagents ($664,401 through September 2027) and from VISN 22 for a large coagulation CPT order ($846,064 through December 2026). The company also carries smaller but numerous calls across VISNs 4, 5, 16, 17, 20, and 21, as well as the Indian Health Service and Military Sealift Command.

Customer concentration aligns strongly with the Veterans Health Administration. The top five customers by combined potential value account for 50% of all awards: VISN 12 ($82.2 million across 50 awards), VISN 9 ($55.4 million across 137 awards), VISN 16 ($35.3 million across 309 awards), Defense Health Agency ($33.8 million across 75 awards), and VISN 4 ($26.9 million across 210 awards). By award count, VISN 16 leads at 309 awards ($35.3 million), followed by Army Medical Command at 242 awards ($21.3 million) and VISN 4 at 210 awards ($26.9 million). This portfolio demonstrates heavy reliance on VA and DoD healthcare procurement rather than civilian agencies.

Diagnostica Stago places work predominantly under the GSA Schedule 66-III for Critical Analyzers, Laboratory Equipment and Supplies (2,165 task orders, $326.1 million), which serves as the company's primary vehicle. Federal Supply Schedule V797P6696A carries 1,095 task orders ($37 million), and several single-award BPAs with individual VISNs provide additional structure. All identified federal contract work flows through these vehicles; the company does not appear to participate in government-wide acquisition contracts (GWACs) or other multi-agency IDIQs.

Recent activity shows modest decline: 90 awards in 2022, 77 in 2023, 78 in 2024, 71 in 2025, and 34 year-to-date in 2026 (reflecting incomplete year). Over the next twenty-four months, 84 awards with a combined potential value of $14.4 million will reach ultimate completion, representing recompete exposure concentrated in VISN and Defense Health Agency task orders. The company holds no subcontract footprint in the source data—4,553 of 4,554 total awards are prime awards, with only one identified sub-award from 2022 to Battelle Memorial Institute on a weapons of mass destruction civil support team contract.

Diagnostica Stago's market position is narrow and specialized: the company supplies a single product category (coagulation and hemostasis analyzers and reagents) across a concentrated customer base (primarily VA VISNs and Defense Health Agency). The business model depends on task order volume through established GSA Schedule vehicles rather than IDV ceiling growth, with no apparent diversification into adjacent diagnostic markets, other federal agencies, or commercial segments. Foreign ownership and absence of SBA designations mean the company does not access small-business or socioeconomic set-asides, competing entirely on capability and pricing in full-and-open procurements.